Optimal Just-in-Time Approach Accelerates Enrollment in Trials

Optimal Just-in-Time Approach Accelerates Enrollment in Trials
Using an approach called Optimal Just-in-Time (JIT) has shortened the start of patient enrollment in clinical trials of both solid tumors and blood cancers from eight months to only two weeks. Among other advantages, the methodology also enabled the recruitment of more diverse patient populations than traditional approaches. Optimal JIT works by establishing a network with pre-negotiated contracts and terms for immediate engagement to search for trial participants. Illustrating the methods’ efficiency, all sites using Optimal JIT — managed by Cancer Treatment Centers of America (CTCA) — were able to enroll patients, which could represent a solution to the current 40% of trials that stop early because of poor enrollment. Also, all identified patients were randomized into a study. “Our collaboration with CTCA demonstrates how we are changing the paradigm of cancer care,” Krystyna Kowalczyk, chief operating officer for Optimal service offerings, said in a press release. “Together, we are creating meaningful opportunities for cancer patients to participate in clinical trials and access innovative therapies close to home, allowing them to receive care within the context of their support networks in their own communities.” Kowalczyk added, “Our goal is to
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *